When people stop a GLP-1 medication, weight usually returns — though rarely all of it, and not because of weak willpower. In the STEP 1 trial extension, adults who came off once-weekly semaglutide regained about two-thirds of the weight they had lost within roughly a year, and their improvements in blood pressure, blood sugar and cholesterol faded as the weight came back.[1] This is physiology, not failure: these drugs quiet appetite and "food noise" while you take them, and when that signal is removed the body's weight-regulation system works to restore lost fat. Because obesity is a chronic condition, many people stay on a lower maintenance dose long-term with their clinician rather than stopping outright.
Why does the weight come back?
GLP-1 receptor agonists — semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which also acts on the GIP receptor — reduce hunger, slow stomach emptying and dial down the intrusive "food noise" that keeps pulling attention toward eating. Those effects depend on the drug being in your system. Semaglutide has a half-life of about a week, so appetite and cravings typically climb back over the days to weeks after the last dose.
The deeper reason regain is so common is that the body defends a higher weight. After weight loss, the Obesity Medicine Association notes, the body "metabolically adapts, often causing an increase in hunger hormones, a decrease in satiety hormones, and a reduced resting metabolic rate" — biology that actively pushes weight back up.[6] Regain after stopping "should not be viewed as a failure of the medication to work," the group writes, "but as a consequence of weight-loss-associated metabolic adaptation."[6] The medication was doing real work; removing it removes that counterweight.
It helps to think of a GLP-1 the way clinicians think of a blood-pressure pill or a statin. Stop those and blood pressure or cholesterol drifts back up — no one calls that a failure of the drug or the patient. Obesity behaves the same way: the Obesity Medicine Association classes it as a chronic disease whose "treatment should be viewed as long-term, similar to diabetes and hypertension."[6] Regain is the expected result of removing an effective treatment, not proof the treatment was pointless.
What the withdrawal trials actually found
Three randomized trials give the clearest picture, and they point the same way.
STEP 1 extension (semaglutide). Adults lost an average of 17.3% of body weight over 68 weeks on semaglutide. In the year after stopping the drug and its lifestyle support, they regained about 11.6 percentage points — roughly two-thirds of what they had lost — settling near 5.6% below their starting weight. Blood pressure, lipids and blood sugar drifted back toward baseline alongside the weight.[1]
SURMOUNT-4 (tirzepatide). After about 36 weeks on tirzepatide (mean loss around a fifth of body weight), participants were split: those who continued lost a further ~5.5%, while those switched to placebo regained about 14% — a gap of roughly 19 percentage points. Most of the withdrawal group regained more than a fifth of the weight they had lost — only about 17% kept at least 80% of their loss — and cardiometabolic measures such as waist size, blood pressure and fasting insulin worsened in step with the regain.[3]
STEP 4 (the other side of the coin). STEP 4 tested staying on the drug. People who kept taking semaglutide after a run-in period continued to lose weight, reaching about 17% total, while those switched to placebo steadily regained — direct evidence that it is continued treatment that maintains the loss.[2]
| After you stop | What studies show | What may help (clinician-guided) |
|---|---|---|
| Body weight | About two-thirds of lost weight regained within ~1 year off semaglutide (STEP 1); most people regained more than a fifth of their loss after stopping tirzepatide (SURMOUNT-4).[1][3] | Discuss a maintenance dose versus stopping; avoid an abrupt halt; keep lifestyle supports in place. |
| Blood pressure, cholesterol, blood sugar | Improved on treatment, then drifted back toward baseline as weight returned.[1][3] | Keep monitoring; treat cardiometabolic risk directly, not only through the drug. |
| Appetite & "food noise" | Return over days to weeks as the drug clears (semaglutide half-life ≈ 1 week). | Lean on protein, fiber, sleep and stress routines; expect hunger to rise — it's biology, not failure. |
| Muscle & metabolic rate | Some lean mass is lost during weight loss; less muscle lowers resting energy use. | Protein plus resistance training to preserve muscle before and during any taper. |
| Reason for stopping | Unplanned stops — denial, shortage, cost — tend to drive faster rebound. | Appeal denials, plan the transition, use cost and coverage help before quitting. |
How fast does the weight come back?
Faster than many people expect. In the STEP 1 extension, regain after semaglutide was quicker than in earlier obesity-drug withdrawal studies, tracking the return of appetite as the medication cleared over the first weeks and then building steadily across the following months.[1] By one year off treatment, weight had not climbed all the way back to baseline, but the trajectory was clearly upward. The practical lesson is that the transition window — the first few months after a dose stops — is when structure matters most. A planned, clinician-guided step-down may land more gently than an abrupt stop, though head-to-head evidence comparing tapering with stopping outright is still limited.
Is regain inevitable or total?
No. Regain is common, but it is usually partial and it varies widely between people. A year after stopping semaglutide, STEP 1 participants were still meaningfully below where they started.[1] In SURMOUNT-4, people who held on to more of their weight loss also kept more of their cardiometabolic improvements.[3] How much comes back is shaped by genetics, how much muscle was preserved, how the drug was stopped, and the habits around the transition. Averages describe groups, not your outcome.
What influences regain — and what can soften it
Ongoing treatment, not a finish line
The biggest lever is often whether treatment continues at all. Leading obesity organizations — The Obesity Society, the Obesity Medicine Association and the Obesity Action Coalition — state that FDA-approved obesity medications are appropriate for long-term use, even after reaching a goal weight, to preserve the benefits and prevent regain.[7] In practice, maintenance can mean continuing treatment, or a clinician settling on the lowest dose that holds your weight steady; the key finding from STEP 4 is that it is continued treatment, not simply a lower target, that keeps the loss in place.[2] Whether you stay on your current dose, step down, or stop entirely is a decision for you and your prescriber — not something to improvise. For the fuller picture, see what happens when you stop a GLP-1 and how GLP-1 medications work.
Don't let a forced, abrupt stop drive the rebound
Some of the fastest regain follows stops that were never planned — a coverage denial, a supply gap, or sticker shock. If cost or access is the pressure, there are paths to try before quitting cold: you can appeal an insurance denial, work through prior authorization, understand the current shortage and compounding status, and compare real prices in our guide to Wegovy cost or with the cost & coverage estimator. If a stop is genuinely unavoidable, planning the transition with a clinician beats an overnight halt.
Protect muscle on the way down
Weight lost on a GLP-1 includes some muscle, and lower muscle means a lower resting metabolic rate — which can make regain easier. Preserving lean mass with adequate protein and regular resistance training is one of the few things within your control that plausibly softens the landing. See GLP-1 and muscle loss, strength training for women, and high-protein eating. This is mechanistically sound and increasingly emphasized, though trials proving it specifically prevents regain are still emerging. It matters even more in midlife: women already lose muscle and bone faster around menopause, so protecting lean mass during and after GLP-1 weight loss is doubly worthwhile — see muscle loss in menopause.
What about microdosing or "maintenance hacks"?
Online you'll see "microdosing," longevity spins and DIY maintenance protocols promising the benefits without the cost. There is no trial evidence that self-directed microdosing prevents regain, and sourcing unregulated or compounded product to do it carries real safety risks. If access is the problem, the answer is a legitimate prescription with clinician oversight — see how to get a GLP-1 online safely — not grey-market dosing.
Two safety notes if you're rethinking your GLP-1
Pregnancy. GLP-1 medications are not considered safe in pregnancy. The Wegovy label advises discontinuing at least two months before a planned pregnancy because semaglutide clears the body slowly; if you could become pregnant, that timing is a conversation to have with your clinician.[4]
Contraception. Tirzepatide (Mounjaro, Zepbound) can reduce the effectiveness of oral birth control by slowing stomach emptying; its label advises switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase.[5] Semaglutide (Ozempic, Wegovy) does not carry this warning. That distinction matters when you're weighing whether to start, switch or stop. Read more on semaglutide and tirzepatide.
When to see a doctor
This article is a reference, not a diagnosis, and the choice to stop, continue or change any medication is your prescriber's to make with you. Contact a clinician — urgently where noted — if you experience:
- Severe, persistent abdominal pain, sometimes radiating to the back and with nausea or vomiting — a possible sign of pancreatitis. Seek care promptly.
- A possible pregnancy while taking a GLP-1 — tell your clinician right away.
- Rapid regain paired with returning problems such as rising blood pressure or blood sugar, so your cardiometabolic risk can be reassessed and treated on its own terms.
- Any plan to stop, restart, step down or switch — including because of cost or supply — so the transition can be managed rather than abrupt.
The goal is not to fear stopping, but to make it — or the choice to keep going — a deliberate, supported decision rather than an accident of cost or supply. For the bigger picture on midlife weight, hunger and hormones, see our weight & metabolism hub and menopause weight gain.
